Edward S. Kim, MD

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses data from the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the prevalence of hyperprogression and pseudoprogression in patients who receive immunotherapy.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the need to develop EAPathways as an improved decision-making tool for oncologists during the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of patients with non-small cell lung cancer (NSCLC).